Muutke küpsiste eelistusi

E-raamat: Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop

  • Formaat: 138 pages
  • Ilmumisaeg: 25-Apr-2022
  • Kirjastus: National Academies Press
  • Keel: eng
  • ISBN-13: 9780309269315
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 32,49 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: 138 pages
  • Ilmumisaeg: 25-Apr-2022
  • Kirjastus: National Academies Press
  • Keel: eng
  • ISBN-13: 9780309269315
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The evolution of health care is expanding the possibilities for integration of clinical research into the continuum of clinical care; new approaches are enabling the collection of data in real-world settings; and new modalities, such as digital health technologies and artificial intelligence applications, are being leveraged to overcome challenges and advance clinical research. At the same time, the clinical research enterprise is strained by rising costs, varying global regulatory and economic landscapes, increasing complexity of clinical trials, barriers to recruitment and retention of research participants, and a clinical research workforce that is under tremendous demands.



Looking ahead to 2030, the Forum on Drug Discovery, Development, and Translation of the National Academies of Sciences, Engineering, and Medicine convened a public workshop for stakeholders from across the drug research and development life cycle to reflect on the lessons learned over the past 10 years and consider opportunities for the future. The workshop was designed to consider goals and priority action items that could advance the vision of a 2030 clinical trials enterprise that is more efficient, effective, person-centered, inclusive, and integrated into the health care delivery system so that outcomes and experiences for all stakeholders are improved. This Proceedings of a Workshop summarizes the presentations and discussions that took place during the four-part virtual public workshop held on January 26, February 9, March 24, and May 11, 2021.

Table of Contents



Front Matter 1 Introduction 2 Defining the Vision 3 Enhancing Outcomes in a More Person-Centered and Inclusive Clinical Trials Enterprise 4 Practical Applications for Technology to Enhance the Clinical Trials Enterprise 5 Building a More Resilient, Sustainable, and Transparent Clinical Trials Enterprise 6 Opportunities for Transformation References Appendix A: Health Affairs Blog Posts Appendix B: Speaker and Moderator Biographies Appendix C: Workshop Agendas
Acronyms and Abbreviations xvii
1 Introduction
1(4)
Organization of the Workshop and Proceedings
3(2)
2 Defining the Vision
5(14)
Envisioning a More Person-Centered and Inclusive Clinical Trials Enterprise
6(3)
Envisioning an Optimized Clinical Trials Enterprise Through the Use of Technologies
9(4)
Envisioning a More Resilient, Sustainable, and Transparent Clinical Trials Enterprise
13(6)
3 Enhancing Outcomes In A More Person-Centered And Inclusive Clinical Trials Enterprise
19(16)
The Road to 2030: Perspectives from the Field
20(4)
The Road to 2030: Visions of What Is Possible
24(8)
Reflections on Achieving Person-Centered and Inclusive Trials
32(3)
4 Practical Applications For Technology To Enhance The Clinical Trials Enterprise
35(14)
The Road to 2030: Perspectives from the Field
36(4)
The Road to 2030: Visions of What Is Possible
40(5)
Reflections on Realizing the Potential of Technology in Clinical Trials
45(4)
5 Building A More Resilient, Sustainable, And Transparent Clinical Trials Enterprise
49(20)
The Road to 2030: Perspectives from the Field
50(7)
The Road to 2030: Visions of What Is Possible
57(9)
Reflections on Resilience, Sustainability, and Transparency of the Clinical Trials Enterprise
66(3)
6 Opportunities For Transformation
69(10)
Opportunities to Transform the Clinical Trials Enterprise
70(3)
Innovating for 2030 Now
73(2)
Taking the Lessons from the COVID-19 Pandemic Response Forward
75(2)
Closing Remarks
77(2)
REFERENCES
79(2)
APPENDIXES
A Health Affairs Blog Posts
81(2)
B Speaker and Moderator Biographies
83(24)
C Workshop Agendas
107